Grow through Strategic Collaborations
The rising costs of M&A and R&D continue to challenge the global pharmaceutical industry. This means CEOs need to explore ever more innovative ways to create business value, such as those presented through strategic collaborations. Initiating and maintaining strategic partnerships can be a complex process. They require trust, robust processes, and most importantly, courage. But […]
Digital Marketing is no Substitute for Sound Strategic Marketing
In recent years, the pharmaceutical industry has rushed to embrace ‘digital marketing’. When done well, this has the potential to generate tangible benefits for companies. However, the fundamentals of strategic marketing cannot be forgotten, otherwise digital initiatives risk becoming a waste of both time and money that fail to deliver value. In this report, we […]
Manage R&D to Create Value
It wasn’t long ago that Morgan Stanley urged pharmaceutical companies to “Exit Research and Create Value”, but the reality today is more complicated. We firmly believe that an excellent internal R&D organisation has the potential to create better products faster, rather than leaving R&D to others. To turn this into a reality, pharmaceutical companies need […]
Business growth: Bespoke strategists lead the way
The pharmaceutical industry continues to evolve, with both drug approvals and the cost of making new drugs trending upwards. Despite ruthless cost-cutting and reducing investment in both commercial and R&D infrastructure, the world’s top pharmaceutical companies continue to grow their top-line revenue. In our white paper, we classify leading companies into three segments to illustrate […]
Funding clinical development: More creativity required?
Securing adequate funding for clinical development remains a central challenge for pharmaceutical companies as they and their investors appear less willing to finance development through their P&L accounts than they are to find cash for deal-making and M&A. However, alternative funding models have started to emerge that can provide access to capital with control over […]
A Biotech-like Mentality: The Winning Combination?
In an effort to address declining R&D productivity in the pharmaceutical industry, many pharma companies look to the innovative entrepreneurialism of top performing biotech companies, leading to numerous changes to operating models and culture. But what is the real “biotech-like” mentality that the industry is seeking? In this paper, we characterise what sets the […]